Non-tuberculous mycobacteria in patients with bronchiectasis

M Wickremasinghe, L J Ozerovitch, G Davies, T Wodehouse, M V Chadwick, S Abdallah, P Shah, R Wilson

Background: Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms. Patients with pre-existing lung damage are susceptible to NTM, but their prevalence in bronchiectasis is unknown. Distinguishing between lung colonisation and disease can be difficult.

Methods: A prospective study of 100 patients with bronchiectasis was undertaken to evaluate the prevalence of NTM in sputum, and a retrospective analysis of clinical, microbiological, lung function and radiology data of our clinic patients with NTM sputum isolates over 11 years was performed.

Results: The prevalence of NTM in this population of patients with bronchiectasis was 2%. Patients in the retrospective study were divided into three groups: bronchiectasis + multiple NTM isolates (n = 25), bronchiectasis + single isolates (n = 23), and non-bronchiectasis + multiple isolates (n = 22).

Conclusions: NTM are uncommon in non-cystic fibrosis bronchiectasis. Routine screening identifies otherwise unsuspected patients. MAC is the most frequent NTM isolated.
sputum examination for AFB. Patients referred because of known mycobacterial infection and those with a positive sweat test indicative of cystic fibrosis were excluded. Sputum was sent for smear and culture examination on three separate occasions (0, 6, and 12 months). At the time of this study it was not our practice to screen routinely for NTM except during the patient’s initial investigations in our unit.

**Retrospective study population**
A retrospective analysis over 11 years from 1991 to 2001 of patients in the Host Defence Unit with a positive NTM sputum culture was performed using the Royal Brompton Hospital Department of Microbiology database. Case notes were reviewed and patients allocated to the following groups: (1) patients with bronchiectasis and a single NTM isolate; (2) patients with bronchiectasis and multiple NTM isolates; and (3) patients with non-bronchiectasis lung disease and multiple NTM isolates.

All patients had daily sputum production and a history of recurrent infective exacerbations. The diagnosis of bronchiectasis was made by HRCT scanning. Patients with bronchiectasis and multiple isolates were analysed for age, sex, aetiology of bronchiectasis, whether the NTM infection was primary or secondary, past medical history, drug history, sputum microbiology, HRCT appearance, lung function, and drug treatment.

**Microbiology**
Samples were processed for mycobacteria using the modified Petroff’s 4% sodium hydroxide method. The processed samples were then inoculated onto two Lowenstein-Jensen slopes (one with pyruvate and one with glycerol). AFB positive smear samples were also inoculated into Middlebrook >H12 Bactec vials. Positive cultures were identified by biochemical and temperature tests and, where appropriate, Accuprobe. The criteria for multiple isolates were two isolates that were cultured more than 1 week apart. Single isolates were a single positive NTM culture listed in the microbiology database. The presence of negative cultures before and after the single isolate was confirmed and the presence or absence of smear positivity was documented. Sputum was sent at the same time as AFB examination for routine bacteriological examination. Pathogens cultured within 1 week of the first or single NTM isolate were documented and described as a co-cultured pathogen. These were described as chronic isolates if grown on more than two successive occasions.

**Lung function**
Airflow obstruction, gas trapping, and gas transfer were measured since these are usually impaired in bronchiectasis. Forced expiratory flow in 1 second (FEV1), maximum expiratory flow with 50% of vital capacity remaining in lung (MEF50), residual volume (RV), and carbon monoxide transfer factor (TLCO) were measured. Lung function nearest the time of the first isolate was compared with the most recent set of lung function data recorded.

**Radiology**
All HRCT scans were performed at the Royal Brompton Hospital. The timing of the first HRCT scan with respect to the first NTM isolate was calculated. The predominant location of bronchiectasis, severity, presence or absence of nodules, mucus plugging, cavitation, consolidation, infiltrates, and dyshomogeneity (air trapping) was assessed.

**Statistical analysis**
Group comparisons were made using χ² or Fisher’s exact test as appropriate. Lung function data were analysed using paired t tests. A p value of <0.05 was regarded as statistically significant.

**RESULTS**

**Prospective study of NTM in sputum from patients with bronchiectasis**
Of the 50 newly referred patients with bronchiectasis, one had multiple *Mycobacterium avium* complex (MAC) isolates. This was a 52 year old woman referred because of poor symptom control and chronic *Staphylococcus aureus* infection. Investigation showed idiopathic bronchiectasis and an HRCT scan with an unusual pattern of bronchiectasis involving the anterior segment of the right upper lobe and right middle lobe with marked dyshomogeneity suggesting small airways disease. The sputum had not been previously investigated for mycobacteria. Another patient had a single *M chelonae* isolate that was never repeated.

Of the 50 patients with bronchiectasis who were being followed up, one had multiple MAC isolates. This 64 year old woman had a 10 year history of allergic bronchopulmonary aspergillosis and seropositive rheumatoid arthritis. During initial assessment she was smear and culture negative for mycobacteria and had widespread severe bronchiectasis with a left apical cavity and mycetoma. She was stable over the next 8 years, after which she was enrolled into the study and her sputum sent for this purpose was smear and culture positive for MAC on all three occasions.

The prevalence of NTM in this population of patients with bronchiectasis in our Host Defence Unit was therefore 2% over 1 year. The two patients were regarded as being colonised as their condition was well controlled with general treatment. The first patient improved with broad spectrum antibiotics and physiotherapy; the second patient remained stable for several years but then became more symptomatic and a new CT scan showed several cavitatory nodules. Treatment was commenced at that time.

**Demographic data of patients in retrospective study**
Seventy one patients with NTM isolates were identified over 11 years: 23 with bronchiectasis and single NTM isolates (single NTMB group), 25 with bronchiectasis and multiple NTM isolates (multiple NTMB group), and 22 with multiple NTM isolates and non-bronchiectatic lung disease.

There was a female preponderance in both the single (9 men, 14 women) and multiple NTMB groups (9 men, 16 women). The mean age at identification of first isolate in the multiple NTMB group was 62.2 years (men: 62.3 years (range 26–78); women: 62.1 years (range 43–85)). In contrast, the single NTMB group was younger (mean age 55.1 years; men: 50.5 years, women: 58.1 years), as were those with non-bronchiectasis lung disease and multiple isolates (mean age 47.2 years).

In the multiple NTMB group 52% were non-smokers and 40% were ex-smokers. Only 8% of patients with bronchiectasis were current smokers compared with 27% of patients with non-bronchiectasis lung disease. 24% of the multiple NTMB group were on oral steroids at the time of the first isolate and 16% had a history of lobectomy. There was one patient of non-Caucasian origin in each group.

Sputum samples were sent at the time of first isolate for a variety of reasons: 32% were referred to our unit with known NTM, 28% were sent during routine surveillance, 16% due to suggestive CT changes, 16% due to suggestive symptoms (cough, weight loss, fever, increased sputum, malaise, breathlessness), and only 8% because of failure to respond to usual bronchiectasis treatment.

**Comparison of NTM species in the three patient groups in the retrospective study**
MAC was by far the most common species identified in the multiple and single NTMB groups (table 1); in the non-bronchiectasis group *M kansasii* and *M xenopi* predominated.
The causes of bronchiectasis in the multiple NTMB group were 24% idiopathic, 24% post-tuberculous (all MAC), 12% rheumatoid arthritis (all MAC), and 8% each for post childhood infections, post adult infections, and primary ciliary dyskinesia. There was one each of pulmonary lymphangioleiomyomatosis, pulmonary sarcoidosis, allergic bronchopulmonary aspergillosis, and a compound heterozygote for cystic fibrosis with normal sweat test (M. chelonae). Patients were not tested for HIV, but none were in high risk groups for this condition nor had lymphopenia.

In six patients (24%), all who cultured MAC, the bronchiectasis was considered to be a consequence of primary NTM infection. In these cases the possibility of pre-existing bronchiectasis before NTM infection could not be excluded. However, the NTM infection was judged to have either led to marked progression of disease on the HRCT scan or to have been the sole cause of the bronchiectasis. Three of these patients also had rheumatoid arthritis, and one was a middle aged woman with a persistent dry cough whose bronchiectasis was present in the middle lobes, a pattern which has been described as Lady Windermere syndrome.15

### Microbiological results of patients in the retrospective study

Patients in the single NTMB group were more likely to be smear negative (83.3%) than those in the multiple NTMB group (15.7%, p<0.0001). In the multiple NTMB group, 84% of smear positive sputum samples grew MAC in first isolates compared with 33.3% of smear negative samples. All of the three plus smear positive sputum samples grew MAC; non-MAC species were much less likely to be smear positive (15.7%).

_Pseudomonas aeruginosa_ was a co-pathogen at the time of first isolation of NTM in 52% of the multiple NTMB group, but isolation of _P. aeruginosa_ in these patients was chronic in only 16%. 61% of patients with multiple MAC isolates cultured _P. aeruginosa_ compared with 28% of patients with non-MAC isolates. _S. aureus_ was co-cultured frequently in the multiple NTMB group (7/25, 28%). Co-culture of _P. aeruginosa_ and _S. aureus_ occurred less often in the single NTMB group (39% and 21.7%, respectively) than in the multiple NTMB group. Rarer co-pathogens in the multiple NTMB group included _Haemophilus influenzae_ (12%), _Aspergillus fumigatus_ (4%), _Candida albicans_ (8%), and _Stenotrophomonas maltophilia_ (4%).

### HRCT scan at time of first isolate in the retrospective study

Twenty four of the 25 patients in the multiple NTMB group underwent HRCT scanning (one patient had severe bronchiectasis previously shown by bronchography). Twenty HRCT scans were performed within 6 months of identification of the first NTM isolate (17 of these were performed within 1 month of the first isolate). Two HRCT scans were performed 9 months before identification of the first NTM isolate, one 7 months after, and one 11 months after.

Most of the patients had widespread bronchiectasis (table 2). Because of numbers of patients, comparisons were made between MAC and non-MAC species. Nodules, mucus plugging, and dyshomogeneity were common features and a quarter had cavities. MAC accounted for five of the six patients with cavities and consolidation (83.3%) and for 78.6% of nodules and mucus plugging compared with non-MAC species. Dyshomogeneity had a similar prevalence in both groups. Patients requiring treatment had more cavities (33.3% v 9.1%), consolidation (41.6% v 9.1%), and had more severe (58.3% v 18.2%) and widespread (75% v 45.4%) bronchiectasis than those who did not.

<table>
<thead>
<tr>
<th>Table 1 Comparison of species isolated in the three groups in the retrospective study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><em>M. avium</em> complex (MAC)</td>
</tr>
<tr>
<td><em>M. kansasii</em></td>
</tr>
<tr>
<td><em>M. chelonae</em></td>
</tr>
<tr>
<td><em>M. fortuitum</em></td>
</tr>
<tr>
<td><em>M. malmoense</em></td>
</tr>
<tr>
<td><em>M. xenopi</em></td>
</tr>
</tbody>
</table>

Data are shown as number of patients with percentage of total in parentheses.

<table>
<thead>
<tr>
<th>Table 2 HRCT appearances in patients with bronchiectasis and multiple NTM isolates in the retrospective study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Bronchiectasis distribution</strong></td>
</tr>
<tr>
<td>Widespread</td>
</tr>
<tr>
<td>Lower and middle lobes</td>
</tr>
<tr>
<td>Lower lobes</td>
</tr>
<tr>
<td>Upper and middle lobes</td>
</tr>
<tr>
<td>Lower and upper lobes</td>
</tr>
<tr>
<td>Localised</td>
</tr>
<tr>
<td>Middle lobe and lingula</td>
</tr>
<tr>
<td>Upper lobe</td>
</tr>
<tr>
<td><strong>Specific HRCT features</strong></td>
</tr>
<tr>
<td>Nodules and mucus plugging</td>
</tr>
<tr>
<td>Dyshomogeneity</td>
</tr>
<tr>
<td>Cavities</td>
</tr>
<tr>
<td>Consolidation</td>
</tr>
<tr>
<td>Infiltrates</td>
</tr>
</tbody>
</table>

Data are shown as number of patients with percentage of total in parentheses.
Lung function in the retrospective study

Lung function data were analysed for 22 patients in the multiple NTMB group (two patients had incomplete lung function data, one patient underwent surgery for NTM and was excluded). These were analysed as follows: those considered not to require treatment (N = 11), those who had completed antimycobacterial treatment (N = 5), and those continuing on antimycobacterial treatment (N = 6). For each patient group, lung function data nearest to the time of the first NTM isolate was taken (median time 2 ± 2 days before NTM isolate, range −8 to +11 months) and compared with the latest lung function data available.

In colonised patients the mean (SE) FEV1 was 60.7 (4.1)% compared with 55.0 (8.9)% in drug treated patients at first isolate (difference non-significant; fig 1). Untreated patients with NTM had stable lung function, although there was a trend for increasing FEV1 and MEF50 and decreasing RV over time (difference non-significant). This might be due to general measures such as physiotherapy taken to improve the control of the bronchiectasis. Patients who had completed antimycobacterial treatment also had stable lung function (fig 2), while those still receiving antimycobacterial treatment showed a rise in RV over time (133% rising to 150%) and a fall in MEF50 (p<0.05; fig 3).

Management in the retrospective study

Of the 25 patients in the retrospective study, 11 were considered not to require antibiotic treatment. Reasons for deciding to monitor rather than to treat included having a stable clinical condition with routine management and no HRCT evidence of active NTM disease. There was no species difference between the monitored and the treated group (64.3% MAC in treated group v 72.7% in the monitored group).

Of the remaining 14 patients, one underwent surgical resection of a cavity having previously completed 1 year of antimycobacterial treatment at the referring hospital and 13 were prescribed antimycobacterial drugs. The reasons for initiating treatment were multifactorial but HRCT changes influenced the decision in 11 of 13 (84.6%). These were progressive bronchiectasis (36.4%), new nodules (27.3%), new/progression of cavities (36.4%), and consolidation (18.1%). Failure of symptoms to respond to usual treatment was a reason in 27.3%; common symptoms in this regard were cough (45.4%) and weight loss (36.4%).

DISCUSSION

Patients are admitted to our minimal dependency unit for planned investigations at a time when their condition is stable, but they have usually been referred to our unit which is in a tertiary centre because their condition is causing concern. Similarly, patients followed up regularly in our clinics are usually more complicated than those seen in a general respiratory clinic.

The prevalence of NTM in our bronchiectatic population was 2%. Previous studies have found a similar low prevalence, so it is likely that the prevalence of NTM in an unselected bronchiectasis population would be even lower than in our study.8–10

This is the first study to show that MAC is the predominant NTM species isolated from the sputum of patients with non-cystic fibrosis bronchiectasis, both in single (45.5%) and multiple isolates (72%). This suggests that patients with bronchiectasis are susceptible to contracting MAC and, in some of these cases, long term colonisation or infection is established. In contrast, in our series and those of others,10 the species profile of NTM in patients without bronchiectasis is very different, with M kansasii and M xenopi predominating and MAC present in less than 10% of cases.16 17 M xenopi was found in only one single isolate and in no multiple isolates in patients with bronchiectasis. Single isolates are usually thought to represent environmental exposure just before the sample is taken. However, the predominance of MAC in single as well as multiple isolates suggests that, in
Figure 2  Mean (SE) lung function data (percentage predicted) in patients with bronchiectasis and multiple non-tuberculous mycobacteria isolates (NTMB) who were still on treatment and were sputum positive for NTM (N=4) after treatment. Each patient is represented as cases 1–4. Mean duration of treatment 13.7 months. Lung function measured near the time of first NTM isolate (diagnosis) was compared with latest available lung function data (mean 12.25 months later). Mean (SE) percentage predicted values at diagnosis and later are as follows: FEV1: 56 (11) v 49 (9); MEF50: 33 (21) v 31 (18); RV: 135 (21) v 135 (17); TLCO: 58 (15) v 47 (12).

Figure 3  Mean (SE) lung function data (percentage predicted) in patients with bronchiectasis and multiple non-tuberculous mycobacteria isolates (NTMB) who had finished treatment and were sputum negative for NTM (N=4) after treatment. Each patient is represented as cases 1–4. Mean duration of treatment 16.7 months. Lung function measured near the time of first NTM isolate (diagnosis) was compared with latest available lung function data (mean 60 months later). Mean (SE) percentage predicted values at diagnosis and later are as follows: FEV1: 54 (20) v 56 (18); MEF50: 33 (21) v 31 (18); RV: 135 (21) v 135 (17); TLCO: 58 (15) v 47 (12).
Bronchiectasis, single isolates might represent temporary colonisation and the difference in species profile compared with non-bronchiectasis is probably due to unidentified factors causing a predisposition to infection. Since no particular cause of bronchiectasis was associated with NTM or MAC infection, this is likely to be due to the local environment of the bronchiectatic airway.

Pulmonary MAC disease is reported to present in two ways. The first is a classical presentation of fibrocavitatory lung disease in patients with either smoking related chronic obstructive pulmonary disease (COPD), previous tuberculosis, bronchiectasis, or cystic fibrosis. Those with smoking related COPD are predominantly men aged 50–70 years. A second form of MAC infection has been increasingly recognised to occur in apparently immunocompetent individuals with no pre-existing lung disease. This group consists mainly of non-smoking women aged 40–80 years. These patients have no known pre-existing lung disease but HRCT scanning shows the presence of small nodules most commonly involving the middle lobe and mild cylindrical bronchiectasis. This presentation has been described as the Lady Windermere syndrome because habitual voluntary cough suppression is postulated to account for retained secretions and focal disease in the lingula and middle lobe. After careful examination of the evidence available, we considered six of the 25 multiple NTMB cases to be primary infections. This was based on HRCT appearances, the fact that no other cause of bronchiectasis was identified, and patient history including lack of chronic rhinosinusitis and profound tiredness which is present in most cases of idiopathic bronchiectasis. All six were primary infections with MAC. In primary infections it is usually impossible to be certain whether silent bronchiectasis predisposes to the MAC infection or whether the primary MAC infection itself causes the bronchiectasis in individuals who may have a genetic predisposition. Abnormalities in the gamma interferon pathway have recently been identified. HRCT studies of patients with MAC infection have shown small peripheral nodules which may coalesce and ectatic changes which develop in draining bronchi. Destruction of bronchial wall structure due to extensive granuloma formation in MAC lung infection has also recently been demonstrated.

In our study the patients with bronchiectasis and multiple NTM isolates were predominantly female, which is also true of bronchiectasis in general. However, other features of the group were different from those reported in other bronchiectasis series. The mean age of the group (62.2 years) is higher than in other studies of bronchiectasis—for example, 50.4 years, 52.7 years, and 41.6 years. The single NTMB group in our paper were younger, which suggests that patients with bronchiectasis may be less able to clear NTM to which they are exposed as they get older. Previous studies of bronchiectasis have suggested a negative smoking history with only 1% current smokers. The multiple NTMB group contained 40% ex-smokers and 8% current smokers. This association with cigarette smoking has also been noted with primary MAC infections in which 38% were ex-smokers. Treatment with regular oral corticosteroids and a history of previous lobectomy was also more common than is usual in a general bronchiectasis population.

No particular aetiology of bronchiectasis was associated with NTM isolation. The prevalence of tuberculosis as a cause of bronchiectasis has been found to be 19% or less, and as low as 2%. We found tuberculosis related bronchiectasis in patients with multiple NTM isolates to be more common (24%), which suggests a possible increased general susceptibility to mycobacterial infection. Similarly, the frequency of rheumatoid arthritis was higher than in other studies, either suggesting an immune mechanism for increased susceptibility to NTM or that rheumatoid associated small airways disease predisposes to NTM colonisation. Symptoms of cough, sputum production, and breathlessness are common in bronchiectasis so a high index of clinical suspicion is required to identify NTM. A large number of NTM isolates were detected by routine surveillance (28%) and it is now our practice to screen our patients routinely once a year. Radiological appearances suggestive of NTM also accounted for a high proportion of NTM isolates, reflecting increased knowledge of the HRCT features of NTM lung disease.

Pseudomonas aeruginosa was a frequent co-pathogen with MAC in patients with bronchiectasis and multiple NTM isolates (52%) compared with other studies of bronchiectasis that have reported positive cultures in 20%, 26%, and 31% of patients. However, only a quarter of these were persistent isolates. Patients with bronchiectasis and single isolates also frequently co-cultured P aeruginosa (39%) with MAC. P aeruginosa infection is associated with a greater extent of disease and worse lung function and may be a marker of patients whose lung function is declining.

Co-culture of P aeruginosa and MAC may therefore simply reflect worse bronchiectasis and resulting increased susceptibility to NTM. S aureus is an uncommon pathogen in bronchiectasis and is associated with allergic bronchopulmonary aspergillosis and atypical variants of cystic fibrosis, both diseases which usually manifest as upper lobe disease. However, S aureus was more frequently isolated in patients with bronchiectasis and NTM (28%) than in other published studies. This suggests that repeated isolation of S aureus in bronchiectasis should prompt a search for NTM as well as testing for allergic bronchopulmonary aspergillosis and atypical cystic fibrosis.

In a comparative study of CT appearances of patients infected with NTM species, higher numbers of nodules and more severe bronchiectasis were seen with MAC than with other NTM species. No differences were found in frequency of cavitation, consolidation, or “tree in bud” pattern between MAC and non-MAC species. Although the frequency of cavitation in our study was similar to that in a mixed lung disease population, we found that MAC accounted for the majority of cavities in bronchiectasis. This suggests that, in bronchiectasis, MAC behaves in a more aggressive fashion than non-MAC species, causing greater destruction of lung parenchyma and cavity formation.

Only just over half of the patients with bronchiectasis and multiple isolates were judged to require treatment. The rest were considered to be colonised but careful monitoring was continued, and our results show that lung function and radiology remained stable. Patients who required treatment had more severe impairment of lung function, and this got worse if patients remained on treatment usually due to failure of eradication. A key factor in the decision to treat was evidence of changes on HRCT scanning, especially progression of bronchiectasis and appearance of new cavities. A higher proportion of patients who went on to have treatment had cavities (33.3% vs 9.1%), consolidation (58.3% vs 9.1%), or had more widespread and severe bronchiectasis (75% vs 45%).

In summary, we have shown that, although NTM are uncommon in bronchiectasis, infection can lead to worsening of the condition. A significant number of cases were detected by routine surveillance. MAC is the predominant species whatever the underlying aetiology, and is responsible for most of the cavitatory disease. Patients with bronchiectasis may be more susceptible to MAC. However, pulmonary MAC infection might progress early bronchiectasis into more severe disease in genetically susceptible individuals such as those with rheumatoid arthritis. A proportion of patients...
Non-tuberculous mycobacteria in patients with bronchiectasis

presenting with symptoms of bronchiectasis are probably caused by primary MAC infections in previously normal lungs. HRCT scanning is very important in aiding the decision about when to start treatment.

....................

Authors' affiliations
M Wickremasinghe, L J Ozerovitch, G Davies, T Wadhouse, M V Chadwick, S Abdallah, P Shah, R Wilson, Host Defence Unit, Royal Brompton Hospital, London, UK

Competing interests: none declared.

REFERENCES
Non-tuberculous mycobacteria in patients with bronchiectasis

M Wickremasinghe, L J Ozerovitch, G Davies, T Wodehouse, M V Chadwick, S Abdallah, P Shah and R Wilson

Thorax 2005 60: 1045-1051 originally published online October 14, 2005
doi: 10.1136/thx.2005.046631

Updated information and services can be found at:
http://thorax.bmj.com/content/60/12/1045

These include:
References
This article cites 26 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/60/12/1045#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Screening (epidemiology) (366)
Screening (public health) (366)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/